Status:
COMPLETED
To Demonstrate the Relative Bioavailability of Bupropion HCI 300 mg Extended-Release Tablets Under Fasting Conditions
Lead Sponsor:
Sandoz
Conditions:
Depression
Eligibility:
All Genders
18-58 years
Phase:
PHASE1
Brief Summary
The purpose of this study is to demonstrate the relative bioequivalence of Bupropion HCI 300 mg ER Tablets under fasting conditions.
Eligibility Criteria
Inclusion
- No clinically significant abnormal finding on physical exam, medical history, or clinical laboratory results on screening.
Exclusion
- Positive test results for HIV or hepatitis B orc.
- Treatment for drug or alcohol dependence.
Key Trial Info
Start Date :
March 1 2004
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 1 2004
Estimated Enrollment :
28 Patients enrolled
Trial Details
Trial ID
NCT00861939
Start Date
March 1 2004
End Date
April 1 2004
Last Update
March 29 2017
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.